<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413386</url>
  </required_header>
  <id_info>
    <org_study_id>MIRA-001</org_study_id>
    <nct_id>NCT01413386</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent</brief_title>
  <acronym>MIRAII</acronym>
  <official_title>A Randomized Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent (Niti-S Mira-Cover II Biliary Stent) to the Common Covered Metallic Biliary Stent.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jong Taek, Lee</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taewoong Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paclitaxel covered metal biliary stent is non-inferior to common covered metal biliary stent
      in their patency rate and safety at the 6 months after stenting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paclitaxel covered metal biliary stent (Niti-S Mira-Cover II Biliary Stent) is non-inferior
      to common covered metal biliary stent (Niti-S Biliary Stent_ComVi type)in their patency rate
      and safety at the 6 months after stenting.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Delayed subject enrollment
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 23, 2013</completion_date>
  <primary_completion_date type="Actual">April 18, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accumulative Patency Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accumulative Survival Rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent migration rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possibility of Other Treatment after Obstruction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Biliary Stricture</condition>
  <condition>Malignant Neoplasms</condition>
  <arm_group>
    <arm_group_label>Paclitaxel Eluting Covered Metal Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Covered Metal Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biliary stent</intervention_name>
    <description>palliative treatment for malignant patients</description>
    <arm_group_label>Paclitaxel Eluting Covered Metal Stent</arm_group_label>
    <arm_group_label>Covered Metal Stent</arm_group_label>
    <other_name>Niti-S Mira-Cover II Biliary Stent</other_name>
    <other_name>Niti-S Biliary Stent_ComVi type</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who submitted a written informed consent for the this trial, and 18 ~ 90 years
             old

          -  Patient who have pancreatic cancer and/or biliary cancer with mid or distal CBD
             invasion

          -  Patient who is inoperable and/or unresectable cases of malignant pancreatic stenosis

          -  Patient who is attempting of endoscopic biliary metallic stenting (by ERBD) firstly

          -  Patient who have life expectancy at least longer than 3 months (Karnofsky score &gt;60%)

        Exclusion Criteria:

          -  Patient who previously had surgical biliary drainage

          -  Patient who carrying bleeding disorder

          -  Patient who have combined Hilar and/or intra-hepatic duct cancer

          -  Patient who is improper to endoscopic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ki Lee, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Kangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mung Whan Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Don Haeng Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>In Ha University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>In chun</state>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>July 23, 2017</last_update_submitted>
  <last_update_submitted_qc>July 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Taewoong Medical Co., Ltd.</investigator_affiliation>
    <investigator_full_name>Jong Taek, Lee</investigator_full_name>
    <investigator_title>Taewoong Medical Co., Ltd.</investigator_title>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

